1
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT: MARCH 27, 1995
DATE OF EARLIEST EVENT REPORTED: FEBRUARY 1, 1995
AMGEN BOULDER INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
(FORMERLY KNOWN AS SYNERGEN, INC.)
DELAWARE 0-14339 84-0868248
(STATE OR OTHER JURISDICTION (COMMISSION FILE NUMBER) (IRS EMPLOYER IDENTIFICATION
OF INCORPORATION) NO.)
C/O AMGEN INC.
AMGEN CENTER
1840 DEHAVILLAND DRIVE
THOUSAND OAKS, CA 91320-1789
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
(805) 447-1000
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)
SYNERGEN, INC.
1885 33RD STREET
BOULDER, COLORADO 80301
(FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT)
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
2
ITEM 5. OTHER EVENTS.
As a result of the merger of Amgen Acquisition Subsidiary, Inc., a Delaware
corporation ("Purchaser") with and into Amgen Boulder Inc. (formerly known as
Synergen, Inc.), a Delaware corporation (the "Registrant"), on December 29,
1994, the five classes of the Registrant's outstanding warrants were adjusted
pursuant to their terms so that each warrant no longer represents the right to
purchase shares of common stock of the Registrant, but instead, represents the
right to receive $9.25 in cash for each share of common stock of the Registrant
formerly issuable upon exercise of the warrant upon payment of the relevant per
share exercise price.
On February 1, 1995 the Registrant changed its name from Synergen, Inc. to
Amgen Boulder Inc.
In February, 1995 the Registrant provided written notice of the warrant
adjustment and the name change to the record holders of the warrants, copies of
which are attached hereto as Exhibit 99 and incorporated herein by this
reference.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
99 Notices to holders of outstanding Class A, Class B, Investment Executive,
Development Partner and Joint Venture Warrants of Synergen, Inc.
1
3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
AMGEN BOULDER INC.
By: /s/ Thomas E. Workman, Jr.
--------------------------------
Thomas E. Workman, Jr.
Vice President, Secretary
and General Counsel
Dated: March 27, 1995
2
4
EXHIBIT INDEX
SEQUENTIALLY
EXHIBIT NUMBERED
NUMBER DESCRIPTION PAGE
------ ----------- ------------
99 Notices to holders of outstanding Class A, Class B, Investment
Executive, Development Partner and Joint Venture Warrants of Synergen,
Inc...................................................................